Evidence map›Paper›PMID 29684061›Full record

ArticlePloS one2018

The kinetics of TEM1 antibiotic degrading enzymes that are displayed on Ure2 protein nanofibrils in a flow reactor.

Benjamin Schmuck, Mats Sandgren, Torleif Härd

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Benjamin SchmuckDepartment of Molecular Sciences, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.ORCID 0000-0003-4021-6458
Mats SandgrenDepartment of Molecular Sciences, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.
Torleif HärdDepartment of Molecular Sciences, Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzymatic functionalization of cross-β structured protein nanofibrils has hitherto resulted in a severe reduction of the catalytic efficiency of high turnover biocatalysts. It has been speculated that steric restrictions and mass transport pose limits on the attached enzymes, but detailed kinetics analyzing this have not yet been reported. For a more comprehensive understanding, we studied protein nanofibrils endowed with TEM1, a β-lactamase from Escherichia coli. The packing density of TEM1 along the fibrils was controlled by co-fibrillation; in other words, the N-terminal ureidosuccinate transporter Ure2(1-80) from Saccharomyces cerevisiae was simultaneously aggregated with the chimeric proteins TEM1-Ure2(1-80). The mature fibrils were trapped in a column, and the rate of ampicillin hydrolysis was recorded using a continuous substrate flow. The turnover rate was plotted as a function of substrate molecules available per enzyme per second, which demonstrated that an elevated substrate availability counteracts mass transport limitations. To analyze this data set, we derived a kinetic model, which makes it possible to easily characterize and compare enzymes packed in columns. The functional TEM1 nanofibrils possess 80% of the catalytic turnover rate compared to free TEM1 in solution. Altogether, we have created protein nanofibrils that can effectively hydrolyze β-lactam antibiotic contaminations and provided a groundwork strategy for other highly functional enzymatic nanofibrils.

Indexed as

BioreactorsEnzymes, ImmobilizedNanofibersAmpicillinAnti-Bacterial Agentsbeta-LactamasesBiocatalysisBiodegradation, EnvironmentalEscherichia coliGlutathione PeroxidaseHydrolysisKineticsPrionsProtein MultimerizationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsAmpicillinAnti-Bacterial Agentsbeta-Lactamasesbeta-lactamase TEM-1Enzymes, ImmobilizedGlutathione PeroxidasePrionsSaccharomyces cerevisiae ProteinsURE2 protein, S cerevisiae

Identifiers

PMID29684061
PMCPMC5912753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.